Monday, 26 October 20269:05 am ISTIndia edition

सच, सीधे आप तक

Book ad space

Just in

Health

Denosumab use Beyond 12 Months Linked to Higher Osteonecrosis Risk in Prostate Cancer: JAMA

Image: Business Medical Dialogues. Rights remain with the publisher.

A cohort study in patients with bone-metastatic castration-resistant prostate cancer found that 7–12 months of denosumab treatment was associated with a lower risk of skeletal-related events and a ...

Read the full report on Business Medical Dialogues

Story file

Section
Health
Topics
Health alerts
First reported by
Business Medical Dialogues
Reporter
dr riya dave
Published
Sunday, 25 October 2026, 8:15 pm IST
Coverage
One outlet so far

How this page works. The Headline Update lists this report from Business Medical Dialogues with a short summary and a link to the original. The original reporting and photograph belong to the publisher. Spotted an error in our summary? Tell our corrections desk.

Related stories

More Health news

See all